Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3413]

Buparlisib helps overcome endocrine resistance in metastatic breast cancer:...

Dr Mario Campone - René Gauducheau Centre de Recherche en Cancérologie, Nantes...

Buparlisib helps overcome endocrine resistance in metastatic breast cancer: BELLE-2 trial results ( Dr Mario Campone - René Gauducheau Centre de Recherche en Cancérologie, Nantes, France. )

Molecular evolution of breast cancer during neoadjuvant chemotherapy

Prof Anne-Lise Børresen-Dale - Oslo University Hospital, Oslo, Norway

Molecular evolution of breast cancer during neoadjuvant chemotherapy ( Prof Anne-Lise Børresen-Dale - Oslo University Hospital, Oslo, Norway )

NSABP FB-7: Neoadjuvant therapy with neratinib plus trastuzumab in locally...

Dr Samuel Jacobs - NSABP Foundation, Pittsburgh, USA

NSABP FB-7: Neoadjuvant therapy with neratinib plus trastuzumab in locally advanced HER2-positive breast cancer ( Dr Samuel Jacobs - NSABP Foundation, Pittsburgh, USA )

HER2 status as predictive marker for aromatase inhibitor versus tamoxifen use...

Dr John Bartlett - Ontario Institute for Cancer Research, Toronto, Canada

HER2 status as predictive marker for aromatase inhibitor versus tamoxifen use in early breast cancer ( Dr John Bartlett - Ontario Institute for Cancer Research, Toronto, Canada )

TAILORx: Genomic test helps identify low-risk women who do not need chemotherapy

Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX

TAILORx: Genomic test helps identify low-risk women who do not need chemotherapy ( Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX )

Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study

Dr Javier Cortes - Vall d´Hebron Institute of Oncology, Barcelona, Spain

Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study ( Dr Javier Cortes - Vall d´Hebron Institute of Oncology, Barcelona, Spain )

Editor's choice for December 2015

Prof Gordon McVie - ecancer Editor

Editor's choice for December 2015 ( Prof Gordon McVie - ecancer Editor )

Novel estrogen receptor-targeting agent represents ‘quantum leap’

Dr Ganesh Raj - UT Southwestern Medical Center, Dallas, USA

Novel estrogen receptor-targeting agent represents ‘quantum leap’ ( Dr Ganesh Raj - UT Southwestern Medical Center, Dallas, USA )

Ductal carcinoma in situ: Anastrozole versus tamoxifen

Dr Terry Mamounas - UF Health Cancer Center, Orlando, USA

Ductal carcinoma in situ: Anastrozole versus tamoxifen ( Dr Terry Mamounas - UF Health Cancer Center, Orlando, USA )

Results of the CREATE-X trial

Dr Masakazu Toi - Kyoto University, Kyoto, Japan

Results of the CREATE-X trial ( Dr Masakazu Toi - Kyoto University, Kyoto, Japan )

Hormonal treatments produce similar quality of life outcomes in DCIS

Prof Patricia Ganz - UCLA, Los Angeles, USA

Hormonal treatments produce similar quality of life outcomes in DCIS ( Prof Patricia Ganz - UCLA, Los Angeles, USA )

No significant difference in recurrence rates among women with DCIS taking...

Prof Jack Cuzick - Wolfson Institute of Prevention Medicine, London, United...

No significant difference in recurrence rates among women with DCIS taking anastrozole or tamoxifen ( Prof Jack Cuzick - Wolfson Institute of Prevention Medicine, London, United Kingdom )

More from ecancer